302 related articles for article (PubMed ID: 9760687)
1. The use of esters as prodrugs for oral delivery of beta-lactam antibiotics.
Mizen L; Burton G
Pharm Biotechnol; 1998; 11():345-65. PubMed ID: 9760687
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo evaluations of the metabolism, pharmacokinetics, and bioavailability of ester prodrugs of L-767,679, a potent fibrinogen receptor antagonist: an approach for the selection of a prodrug candidate.
Prueksaritanont T; Gorham LM; Breslin MJ; Hutchinson JH; Hartman GD; Vyas KP; Baillie TA
Drug Metab Dispos; 1997 Aug; 25(8):978-84. PubMed ID: 9280406
[TBL] [Abstract][Full Text] [Related]
3. [Evaluation of the Oral Absorption of Ester-type Prodrugs].
Ohura K
Yakugaku Zasshi; 2020; 140(3):369-376. PubMed ID: 32115554
[TBL] [Abstract][Full Text] [Related]
4. Prodrugs to improve the oral bioavailability of a diacidic nonpeptide angiotensin II antagonist.
Aungst BJ; Blake JA; Rogers NJ; Saitoh H; Hussain MA; Ensinger CL; Pruitt JR
Pharm Res; 1995 May; 12(5):763-7. PubMed ID: 7479565
[TBL] [Abstract][Full Text] [Related]
5. Species differences in the disposition of propranolol prodrugs derived from hydrolase activity in intestinal mucosa.
Yoshigae Y; Imai T; Aso T; Otagiri M
Life Sci; 1998; 62(14):1231-41. PubMed ID: 9570338
[TBL] [Abstract][Full Text] [Related]
6. Species dependent esterase activities for hydrolysis of an anti-HIV prodrug glycovir and bioavailability of active SC-48334.
Cook CS; Karabatsos PJ; Schoenhard GL; Karim A
Pharm Res; 1995 Aug; 12(8):1158-64. PubMed ID: 7494828
[TBL] [Abstract][Full Text] [Related]
7. To be drug or prodrug: structure-property exploratory approach regarding oral bioavailability.
Damião MC; Pasqualoto KF; Polli MC; Parise Filho R
J Pharm Pharm Sci; 2014; 17(4):532-40. PubMed ID: 25579432
[TBL] [Abstract][Full Text] [Related]
8. Species and organ differences in first-pass metabolism of the ester prodrug L-751,164 in dogs and monkeys. In vivo and in vitro studies.
Prueksaritanont T; Gorham LM; Ellis JD; Fernandez-Metzler C; Deluna P; Gehret JR; Strong KL; Hochman JH; Askew BC; Duggan ME; Gilbert JD; Lin JH; Vyas KP
Drug Metab Dispos; 1996 Nov; 24(11):1263-71. PubMed ID: 8937862
[TBL] [Abstract][Full Text] [Related]
9. A novel prodrug approach for tertiary amines. 3. In vivo evaluation of two N-phosphonooxymethyl prodrugs in rats and dogs.
Krise JP; Charman WN; Charman SA; Stella VJ
J Pharm Sci; 1999 Sep; 88(9):928-32. PubMed ID: 10479356
[TBL] [Abstract][Full Text] [Related]
10. Metabolism and pharmacokinetics of novel oral prodrugs of 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs.
Shaw JP; Sueoko CM; Oliyai R; Lee WA; Arimilli MN; Kim CU; Cundy KC
Pharm Res; 1997 Dec; 14(12):1824-9. PubMed ID: 9453075
[TBL] [Abstract][Full Text] [Related]
11. L-type amino acid transporter 1 utilizing prodrugs of ferulic acid revealed structural features supporting the design of prodrugs for brain delivery.
Puris E; Gynther M; Huttunen J; Auriola S; Huttunen KM
Eur J Pharm Sci; 2019 Mar; 129():99-109. PubMed ID: 30625368
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the role of intestinal and liver metabolism in the conversion of two different ester prodrugs of sanfetrinem to the parent drug in vitro and in vivo using different rat tissues and a surgically prepared rat model.
Braggio S; Ferrara A; Sartori M; Bottacini M; Zanelli U; Zonzini L; Petrone M
Eur J Pharm Sci; 2002 Jul; 16(1-2):45-51. PubMed ID: 12113890
[TBL] [Abstract][Full Text] [Related]
13. Intestinal absorption and activation of decitabine amino acid ester prodrugs mediated by peptide transporter PEPT1 and enterocyte enzymes.
Tao W; Zhao D; Sun M; Wang Z; Lin B; Bao Y; Li Y; He Z; Sun Y; Sun J
Int J Pharm; 2018 Apr; 541(1-2):64-71. PubMed ID: 29471144
[TBL] [Abstract][Full Text] [Related]
14. Prodrug design to improve pharmacokinetic and drug delivery properties: challenges to the discovery scientists.
Jana S; Mandlekar S; Marathe P
Curr Med Chem; 2010; 17(32):3874-908. PubMed ID: 20858214
[TBL] [Abstract][Full Text] [Related]
15. Morpholinoalkyl ester prodrugs of diclofenac: synthesis, in vitro and in vivo evaluation.
Tammara VK; Narurkar MM; Crider AM; Khan MA
J Pharm Sci; 1994 May; 83(5):644-8. PubMed ID: 8071813
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and in vivo evaluation of prodrugs of 9-[2-(phosphonomethoxy)ethoxy]adenine.
Serafinowska HT; Ashton RJ; Bailey S; Harnden MR; Jackson SM; Sutton D
J Med Chem; 1995 Apr; 38(8):1372-9. PubMed ID: 7731022
[TBL] [Abstract][Full Text] [Related]
17. Predicting human exposure of active drug after oral prodrug administration, using a joined in vitro/in silico-in vivo extrapolation and physiologically-based pharmacokinetic modeling approach.
Malmborg J; Ploeger BA
J Pharmacol Toxicol Methods; 2013; 67(3):203-13. PubMed ID: 23280406
[TBL] [Abstract][Full Text] [Related]
18. An in-vitro and in-vivo correlative approach to the evaluation of ester prodrugs to improve oral delivery of propranolol.
Shameem M; Imai T; Otagiri M
J Pharm Pharmacol; 1993 Apr; 45(4):246-52. PubMed ID: 8098362
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, ADME properties, and pharmacological activities of β-alanyl-D-histidine (D-carnosine) prodrugs with improved bioavailability.
Orioli M; Vistoli G; Regazzoni L; Pedretti A; Lapolla A; Rossoni G; Canevotti R; Gamberoni L; Previtali M; Carini M; Aldini G
ChemMedChem; 2011 Jul; 6(7):1269-82. PubMed ID: 21634010
[TBL] [Abstract][Full Text] [Related]
20. A novel strategy for ADME screening of prodrugs: combined use of serum and hepatocytes to integrate bioactivation and clearance, and predict exposure to both active and prodrug to the systemic circulation.
Hoppe E; Hewitt NJ; Buchstaller HP; Eggenweiler HM; Sirrenberg C; Zimmermann A; März J; Schwartz H; Saal C; Meyring M; Hecht S
J Pharm Sci; 2014 May; 103(5):1504-14. PubMed ID: 24648352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
